Table 3.

Genetics professionals’ experiences regarding providing genetic counselling for BRCA 1/2, CHEK2 and TP53-mutations during the initial counselling visit

	n	Yes	Sometimes	No
Do you discuss the options of BRCA1/2, CHEK2 and TP53-GT during the initial counselling visit?
A. In case of referral for treatment-focused genetic counselling and testinga	49	73% (36)	27% (13)	–
B. In case of a regular referral	54	58% (33)	33% (19)	4% (2)

Evaluation	n	(Totally) disagree	Neutral	(Totally) agree
In general I am able to provide sufficient information about clinical and genetic aspects of BRCA1/2, CHEK2 and TP53-mutations during a single counselling visit	54	9% (5)	15% (8)	76% (41)
In general I am able to pay enough attention to the decision making process for BRCA1/2, CHEK2 and TP53-GT during a single counselling visit	54	15% (8)	24% (13)	61% (33)
I have difficulties in providing accurate genetic counselling for BRCA 1/2, CHEK2 and TP53 during a single counselling visit	51	55% (28)	18% (9)	28% (14)

Sample size (n) is presented and varies per question due to missing data and because of the fact that some questions do not apply to all respondents. Percentages reflect the proportion of participants selecting the response category divided by the total number of respondents to the corresponding question or statement

LFS Li–Fraumeni syndrome, BC breast cancer, GT genetic testing

^aReferral for treatment-focused genetic counselling and testing is indicated when decisions about primary breast cancer treatment could be impacted by genetic test results